Amundi Has $116.91 Million Holdings in Zimmer Biomet Holdings, Inc. $ZBH

Key Points

• Amundi has reduced its stake in Zimmer Biomet Holdings, Inc. by 10.1%, owning 1,037,760 shares valued at approximately $116.9 million after selling 117,066 shares in Q1.
• Zimmer Biomet reported $2.07 EPS for the last quarter, exceeding analysts' expectations and showing a 7% year-over-year revenue growth at $2.08 billion.
• The company has announced a quarterly dividend of $0.24 per share, which will be paid on October 31, yielding an annualized dividend of 0.9%.

Amundi reduced its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 10.1% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,037,760 shares of the medical equipment provider's stock after selling 117,066 shares during the quarter. Amundi owned about 0.52% of Zimmer Biomet worth $116,914,000 at the end of the most recent reporting period.

A number of other institutional investors also recently made changes to their positions in the company. Vanguard Group Inc. increased its stake in shares of Zimmer Biomet by 0.7% during the first quarter. Vanguard Group Inc. now owns 23,052,925 shares of the medical equipment provider's stock worth $2,609,130,000 after purchasing an additional 166,763 shares during the period. Dodge & Cox grew its holdings in Zimmer Biomet by 2.3% in the 1st quarter. Dodge & Cox now owns 19,564,454 shares of the medical equipment provider's stock valued at $2,214,305,000 after buying an additional 446,018 shares in the last quarter. Ameriprise Financial Inc. increased its position in Zimmer Biomet by 236.0% during the 1st quarter. Ameriprise Financial Inc. now owns 4,568,287 shares of the medical equipment provider's stock worth $517,039,000 after buying an additional 3,208,596 shares during the period. JPMorgan Chase & Co. lifted its holdings in shares of Zimmer Biomet by 251.3% during the first quarter. JPMorgan Chase & Co. now owns 2,081,381 shares of the medical equipment provider's stock worth $235,571,000 after buying an additional 1,488,918 shares in the last quarter. Finally, Dimensional Fund Advisors LP boosted its position in shares of Zimmer Biomet by 2.9% in the first quarter. Dimensional Fund Advisors LP now owns 2,058,898 shares of the medical equipment provider's stock valued at $233,009,000 after acquiring an additional 58,060 shares during the period. Institutional investors own 88.89% of the company's stock.

Analysts Set New Price Targets

A number of equities analysts recently commented on the stock. Evercore ISI lowered their price target on shares of Zimmer Biomet from $102.00 to $96.00 and set an "in-line" rating on the stock in a research report on Tuesday, July 8th. Roth Capital reaffirmed a "buy" rating on shares of Zimmer Biomet in a report on Thursday, August 7th. Canaccord Genuity Group cut their price target on Zimmer Biomet from $115.00 to $101.00 and set a "hold" rating for the company in a research note on Monday, May 12th. UBS Group increased their price target on Zimmer Biomet from $91.00 to $96.00 and gave the stock a "sell" rating in a research report on Friday, August 8th. Finally, Raymond James Financial lifted their price objective on Zimmer Biomet from $104.00 to $113.00 and gave the company an "outperform" rating in a report on Friday, August 8th. Nine investment analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of "Hold" and a consensus price target of $111.00.

Zimmer Biomet Price Performance

Shares of NYSE ZBH traded down $0.87 during trading hours on Tuesday, hitting $103.84. 1,282,597 shares of the stock were exchanged, compared to its average volume of 2,000,891. The company's fifty day simple moving average is $98.69 and its two-hundred day simple moving average is $99.58. The company has a market cap of $20.57 billion, a PE ratio of 25.27, a price-to-earnings-growth ratio of 2.08 and a beta of 0.68. The company has a debt-to-equity ratio of 0.54, a quick ratio of 0.96 and a current ratio of 1.87. Zimmer Biomet Holdings, Inc. has a 1-year low of $89.22 and a 1-year high of $114.72.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last released its earnings results on Thursday, August 7th. The medical equipment provider reported $2.07 earnings per share for the quarter, topping the consensus estimate of $1.98 by $0.09. The firm had revenue of $2.08 billion during the quarter, compared to analysts' expectations of $2.06 billion. Zimmer Biomet had a return on equity of 12.76% and a net margin of 10.51%.The company's quarterly revenue was up 7.0% on a year-over-year basis. During the same period in the prior year, the company earned $2.01 earnings per share. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. On average, sell-side analysts predict that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current year.

Zimmer Biomet Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Tuesday, September 30th will be paid a $0.24 dividend. The ex-dividend date of this dividend is Tuesday, September 30th. This represents a $0.96 annualized dividend and a yield of 0.9%. Zimmer Biomet's dividend payout ratio (DPR) is 23.36%.

Insider Transactions at Zimmer Biomet

In other Zimmer Biomet news, insider Sang Yi sold 1,000 shares of the business's stock in a transaction dated Wednesday, June 11th. The stock was sold at an average price of $95.00, for a total transaction of $95,000.00. Following the completion of the transaction, the insider owned 20,424 shares of the company's stock, valued at approximately $1,940,280. The trade was a 4.67% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.70% of the stock is currently owned by corporate insiders.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.